Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Liabilities (2021 - 2025)

Stoke Therapeutics has reported Other Non-Current Liabilities over the past 5 years, most recently at $1.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 53.95% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 53.95%, while the annual FY2025 figure was $1.1 million, 53.95% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.1 million at Stoke Therapeutics, down from $1.9 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $4.9 million in Q4 2023 and troughed at $959000.0 in Q3 2023.
  • A 5-year average of $2.8 million and a median of $3.0 million in 2022 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 73.43% in 2023 and later surged 218.04% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $3.9 million in 2021, then fell by 24.84% to $3.0 million in 2022, then skyrocketed by 64.56% to $4.9 million in 2023, then plummeted by 49.26% to $2.5 million in 2024, then tumbled by 53.95% to $1.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for STOK at $1.1 million in Q4 2025, $1.9 million in Q3 2025, and $1.3 million in Q2 2025.